Veradigm (MDRX) 10-Q 8 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001124804
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		162,550,390
Entity File Number	001-35547
Entity Tax Identification Number	36-4392754
Entity Address, Address Line One	222 Merchandise Mart
Entity Address, Address Line Two	Suite 2024
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	334-8534
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 204,308	$ 129,668
Restricted cash	7,824	7,871
Accounts receivable, net of allowance of $35,622 and $23,879 as of March 31, 2020 and December 31, 2019, respectively	471,213	459,751
Contract assets, net of allowance of $1,068 and $0 as of March 31, 2020 and December 31, 2019, respectively	98,171	95,982
Prepaid expenses and other current assets	125,677	147,990
Total current assets	907,193	841,262
Fixed assets, net	81,830	88,339
Software development costs, net	250,412	243,929
Intangible assets, net	358,309	374,142
Goodwill	1,361,115	1,362,017
Deferred taxes, net	5,429	5,704
Contract assets - long-term, net of allowance of $4,273 and $0 as of March 31, 2020 and December 31, 2019, respectively	54,501	67,559
Right-of-use assets - operating leases	110,469	98,020
Other assets	123,598	124,767
Total assets	3,252,856	3,205,739
Current liabilities:
Accounts payable	79,168	104,014
Accrued expenses	217,273	270,662
Accrued compensation and benefits	67,635	68,569
Deferred revenue	401,483	379,843
Current maturities of long-term debt	370,751	364,465
Current operating lease liabilities	21,910	23,137
Total current liabilities	1,158,220	1,210,690
Long-term debt	680,434	551,004
Deferred revenue	12,439	12,337
Deferred taxes, net	18,484	21,038
Long-term operating lease liabilities	108,068	95,162
Other liabilities	33,431	30,320
Total liabilities	2,011,076	1,920,551
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of March 31, 2020 and December 31, 2019	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of March 31, 2020 and December 31, 2019; 273,484 and 161,901 shares issued and outstanding as of March 31, 2020, respectively; 272,609 and 162,475 shares issued and outstanding as of December 31, 2019, respectively	2,733	2,725
Treasury stock: at cost, 111,583 and 110,134 shares as of March 31, 2020 and December 31, 2019, respectively	(580,871)	(571,157)
Additional paid-in capital	1,914,816	1,907,348
Accumulated deficit	(87,643)	(49,336)
Accumulated other comprehensive loss	(7,255)	(4,392)
Total stockholders’ equity	1,241,780	1,285,188
Total liabilities and stockholders’ equity	$ 3,252,856	$ 3,205,739

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 35,622	$ 23,879
Contract assets, allowance	1,068	0
Contract assets - long-term, allowance	$ 4,273	$ 0
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	273,484,000	272,609,000
Common stock, shares outstanding	161,901,000	162,475,000
Treasury stock at cost, shares	111,583,000	110,134,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Revenue from contract with customers	$ 416,713	$ 432,049
Cost of revenue:
Amortization of software development and acquisition-related assets	30,641	28,222
Total cost of revenue	259,752	257,954
Gross profit	156,961	174,095
Selling, general and administrative expenses	97,288	100,245
Research and development	62,155	64,310
Asset impairment charges	0	98
Amortization of intangible and acquisition-related assets	6,718	6,797
(Loss) income from operations	(9,200)	2,645
Interest expense	(12,223)	(10,184)
Other income, net	522	513
Recovery of long-term investments	0	1,045
Equity in net income (loss) of unconsolidated investments	200	(64)
Loss from continuing operations before income taxes	(20,701)	(6,045)
Income tax benefit (provision)	347	(1,932)
Net loss	(20,354)	(7,977)
Net loss attributable to non-controlling interests	0	424
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (20,354)	$ (7,553)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share - Basic	$ (0.13)	$ (0.04)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share - Diluted	$ (0.13)	$ (0.04)
Software delivery, Support and Maintenance [Member]
Revenue:
Revenue from contract with customers	$ 263,612	$ 275,512
Cost of revenue:
Total cost of revenue	76,325	81,033
Client services [Member]
Revenue:
Revenue from contract with customers	153,101	156,537
Cost of revenue:
Total cost of revenue	$ 152,786	$ 148,699

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (20,354)	$ (7,977)
Other comprehensive (loss) income:
Foreign currency translation adjustments	(2,512)	695
Change in fair value of derivatives qualifying as cash flow hedges	(473)	132
Other comprehensive income (loss) before income tax (expense) benefit	(2,985)	827
Income tax benefit (expense) related to items in other comprehensive (loss) income	122	(35)
Total other comprehensive (loss) income	(2,863)	792
Comprehensive loss	(23,217)	(7,185)
Comprehensive loss attributable to non-controlling interests	0	424
Comprehensive (loss) income, net	$ (23,217)	$ (6,761)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]	Non-Controlling Interest [Member]
Beginning Balance, Shares at Dec. 31, 2018		270,955	(99,731)
Beginning Balance at Dec. 31, 2018	$ 1,580,427	$ 2,709	$ (460,543)	$ 1,881,494	$ 132,842	$ (5,389)	$ 29,314
Stock-based compensation				11,394
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,058
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 10		(5,338)
Purchase of treasury stock, Shares			(6,148)
Purchase of treasury stock			$ (65,070)
Warrants issued				682
Acquisition of non-controlling interest				(29,913)			(28,890)
Net loss less net loss attributable to non-controlling interests					(7,553)
ASU implementation and ASC tax adjustments | ASU 2016-13					0
Foreign currency translation adjustments, net	695					695
Unrecognized (loss) gain on derivatives qualifying as cash flow hedges,net of tax						97
Net loss attributable to non-controlling interests	(424)						(424)
Ending Balance, Shares at Mar. 31, 2019		272,013	(105,879)
Ending Balance at Mar. 31, 2019	1,456,117	$ 2,719	$ (525,613)	1,858,319	125,289	(4,597)	0
Beginning Balance, Shares at Dec. 31, 2018		270,955	(99,731)
Beginning Balance at Dec. 31, 2018	$ 1,580,427	$ 2,709	$ (460,543)	1,881,494	132,842	(5,389)	29,314
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	1,700
Ending Balance, Shares at Dec. 31, 2019	272,609	272,609	(110,134)
Ending Balance at Dec. 31, 2019	$ 1,285,188	$ 2,725	$ (571,157)	1,907,348	(49,336)	(4,392)	0
Stock-based compensation				9,954
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	900	875
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 8		(3,168)
Purchase of treasury stock, Shares			(1,449)
Purchase of treasury stock			$ (9,714)
Warrants issued				682
Acquisition of non-controlling interest				0			0
Net loss less net loss attributable to non-controlling interests					(20,354)
ASU implementation and ASC tax adjustments | ASU 2016-13					(17,953)
Foreign currency translation adjustments, net	$ (2,512)					(2,512)
Unrecognized (loss) gain on derivatives qualifying as cash flow hedges,net of tax						(351)
Net loss attributable to non-controlling interests	$ 0						0
Ending Balance, Shares at Mar. 31, 2020	273,484	273,484	(111,583)
Ending Balance at Mar. 31, 2020	$ 1,241,780	$ 2,733	$ (580,871)	$ 1,914,816	$ (87,643)	$ (7,255)	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (20,354)	$ (7,977)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	52,092	50,126
Operating right-of-use asset amortization	5,631	5,320
Stock-based compensation expense	9,954	11,658
Deferred taxes	(2,160)	6
Asset impairment charges	0	98
Recovery of long-term investments	0	(1,045)
Other loss (income), net	287	236
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	5,660	32,307
Prepaid expenses and other assets	19,669	3,658
Accounts payable	(23,967)	7,382
Accrued expenses	10,022	(4,847)
Accrued compensation and benefits	(736)	(39,525)
Deferred revenue	724	(17,107)
Other liabilities	2,933	1,380
Operating leases	(6,174)	(5,854)
Accrued DOJ settlement	(57,289)	0
Net cash (used in) provided by operating activities - continuing operations	(3,708)	35,816
Net cash (used in) provided by operating activities - discontinued operations	0	(30,000)
Net cash (used in) provided by operating activities	(3,708)	5,816
Cash flows from investing activities:
Capital expenditures	(2,845)	(4,847)
Capitalized software	(28,556)	(28,600)
(Purchases) sales of equity securities, other investments and related intangible assets, net	(3,028)	32
Other proceeds from investing activities	0	5
Net cash used in investing activities	(34,429)	(33,410)
Cash flows from financing activities:
Taxes paid related to net share settlement of equity awards	(3,174)	(5,327)
Payments for issuance costs on 0.875% Convertible Senior Notes	(758)	0
Credit facility payments	(80,000)	(5,000)
Credit facility borrowings, net of issuance costs	210,000	120,000
Repurchase of common stock	(9,714)	(65,070)
Payment of acquisition and other financing obligations	(2,911)	(55)
Purchases of subsidiary shares owned by non-controlling interest	0	(54,064)
Net cash provided (used in) by financing activities	113,443	(9,516)
Effect of exchange rate changes on cash and cash equivalents	(713)	163
Net increase (decrease) in cash and cash equivalents	74,593	(36,947)
Cash, cash equivalents and restricted cash, beginning of period	137,539	184,795
Cash, cash equivalents and restricted cash, end of period	$ 212,132	$ 147,848

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2020 and 2019 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates. Change in Presentation During the first quarter of 2020, we changed our reportable segments from Provider, Veradigm and Unallocated to Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 15 “Business Segments” for further discussion on the impact of the change. Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported prior period financial results. Significant Accounting Policies We adopted Accounting Standards Update No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” In March 2020, the FASB issued Accounting Standards Update No. 2020-04, “Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), which provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 will be effective for all entities as of March 12, 2020 through December 31, 2022. We adopted ASU 2020-04 on March 12, 2020 , and the adoption had no impact on our consolidated financial statements. Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued Accounting Standards Update No. 2019-12, “ Income Taxes (Topic 740) We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	2. Revenue from Contracts with Customers Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services, which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and project-based revenue from implementation, training and consulting services. For some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees. At March 31, 2020 and December 31, 2019, we had capitalized costs to obtain or fulfill a contract of $19.6 million and $20.8 million, respectively, in Prepaid and other current assets and $34.4 million and $32.9 million, respectively, in Other assets. During the three months ended March 31, 2020 and 2019, we recognized $7.5 million and $7.6 million, respectively, of amortization expense related to such capitalized costs. The amortization of these capitalized costs to obtain a contract are included in Selling, general and administrative expense within our consolidated statements of operations. The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivable, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue. The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2020 Revenue related to deferred revenue balance at beginning of period $ 140,132 Revenue related to new performance obligations satisfied during the period 216,990 Revenue recognized under "right-to-invoice" expedient 58,059 Reimbursed travel expenses, shipping and other revenue 1,532 Total revenue $ 416,713 (In thousands) Three Months Ended March 31, 2019 Revenue related to deferred revenue balance at beginning of period $ 126,184 Revenue related to new performance obligations satisfied during the period 248,221 Revenue recognized under "right-to-invoice" expedient 55,923 Reimbursed travel expenses, shipping and other revenue 1,721 Total revenue $ 432,049 The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”) represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled $4.5 billion as of March 31, 2020, of which we expect to recognize approximately 32% over the next 12 months, and the remaining 68% thereafter. Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment. We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Three Months Ended March 31, (In thousands) 2020 2019 Revenue: Recurring revenue $ 341,219 $ 348,636 Non-recurring revenue 75,494 83,413 Total revenue $ 416,713 $ 432,049 Three Months Ended March 31, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 176,800 $ 76,412 $ 10,400 $ 263,612 Client services 144,739 5,650 2,712 153,101 Total revenue $ 321,539 $ 82,062 $ 13,112 $ 416,713 Three Months Ended March 31, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 193,278 $ 69,357 $ 12,877 $ 275,512 Client services 148,618 4,902 3,017 156,537 Total revenue $ 341,896 $ 74,259 $ 15,894 $ 432,049 Contract Assets – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The new guidance required the recognition of lifetime estimated credit losses expected to occur for contract assets. The guidance also requires we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of the ASU 2016-13 for contract assets was recorded as a debit to retained earnings of $5.3 million as of January 1, 2020. At adoption, we segmented the contract asset population into pools based on their risk assessment. Risks related to contract assets are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment, and business size. The pools are aligned with management’s review of financial performance. For the three months ended March 31, 2020, no adjustment to the pools was necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a t wenty-four - month lookback period of credit memos and adjustments divided by the average contract asset balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. The March 31, 2020 analysis resulted in no change in the ending estimate of credit losses . Changes in the estimate of credit losses for contract assets are presented in the table below. (In thousands) Total Balance at January 1, 2020 $ 5,341 Current period provision 0 Balance at March 31, 2020 $ 5,341 Less: Contract assets, short-term 1,068 Total contract assets, long-term $ 4,273

Accounts Receivables

Accounts Receivables	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Accounts Receivables	3. Accounts Receivable Trade Accounts Receivable – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The new guidance required the recognition of lifetime estimated credit losses expected to occur for trade accounts receivable. The guidance also requires we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of the ASU 2016-13 for trade accounts receivable was recorded as a debit to retained earnings of $12.6 million as of January 1, 2020 At adoption, we segmented the accounts receivable population into pools based on their risk assessment. Risks related to trade accounts receivable are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment, and business size. The pools are aligned with management’s review of financial performance. For the three months ended March 31, 2020, no adjustment to the pools was necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a twelve-month lookback period of credit memos and adjustments divided by the average accounts receivable balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below. (In thousands) Total Balance at January 1, 2020 $ 36,490 Current period provision 994 Write-offs (1,892 ) Recoveries 30 Balance at March 31, 2020 $ 35,622

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Lessee Disclosure [Abstract]
Leases	4. Leases We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease team at commencement date for new leases in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. We have elected the group of practical expedients under ASU 2016-02 to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate and vehicle leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically comprise of executory costs, which under the practical expedient allows for all executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities. Our operating leases mainly include office leases and our finance leases include office and computer equipment leases. Our finance leases are not significant. Our leases have remaining lease terms of approximately 1 year to 9 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year. Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating lease cost (1) $ 6,922 $ 6,717 Less: Sublease income (603 ) (802 ) Total operating lease costs $ 6,319 $ 5,915 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of operations. Supplemental information for operating leases is as follows: (In thousands) Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating cash flows from operating leases $ 7,421 $ 7,287 Right-of-use assets obtained in exchange for operating lease obligations $ 19,913 $ 124,811 The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) March 31, 2020 December 31, 2019 Right-of-use assets - operating leases $ 110,469 $ 98,020 Current operating lease liabilities $ 21,910 $ 23,137 Long-term operating lease liabilities $ 108,068 $ 95,162 Weighted average remaining lease term (in years) 6 6 Weighted average discount rate 3.6 % 4.4 % The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of March 31, 2020. March 31, 2020 (In thousands) Operating Leases Remainder of 2020 $ 20,097 2021 25,996 2022 24,355 2023 22,177 2024 16,633 Thereafter 35,831 Total lease liabilities 145,089 Less: Amount representing interest (15,111 ) Less: Short-term lease liabilities (21,910 ) Total long-term lease liabilities $ 108,068

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business Combinations	5. Business Combinations On July 2, 2019, we acquired the Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology (“ACC”) as part of our broader strategic partnership with the ACC. The total purchase price was $19.7 million, consisting of an initial payment of $11.7 million plus up to an aggregate of $8.0 million pending the attainment certain milestones over the next 18 months. The contingent consideration of up to $8.0 million was valued at $5.0 million at the time of closing. As part of this partnership, we will operate Pinnacle and Diabetes Collaborative Registries, which will extend our EHR-enabled ambulatory network to create a large-scale chronic disease network. The business is included in our Data, Analytics and Care Coordination business segment. On June 10, 2019, we acquired the assets of a business engaged in the development, implementation, customization, marketing, licensing and sale of a specialty prescription drug platform including software that collects, saves and transmits information required to fill a prescription. The drug platform and software will enable healthcare providers, pharmacists and payors to digitally interact with one another to fill a prescription. The business is included in our Data, Analytics and Care Coordination business segment. On March 1, 2019, we acquired all of the outstanding minority interests in Pulse8, Inc., a healthcare analytics and technology company that provides business intelligence software solutions for health plans and at-risk providers to enable them to analyze their risk adjustment and quality management programs, for $53.8 million (subject to adjustments for net working capital and a contingency holdback). We initially acquired a controlling stake in Pulse 8, Inc. on September 8, 2016. This transaction was treated as an equity transaction and the cash payment is reported as part of cash flow from financing activities in the consolidated statement of cash flows for the three months ended March 31, 2019.

Fair Value Measurements and Lon

Fair Value Measurements and Long-term Investments	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements and Long-term Investments	6. Fair Value Measurements and Long-term Investments Fair value measurements are based upon observable and unobservable inputs. Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instruments include the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. The changes in unobservable inputs to the valuation pricing model used to value these instruments is not material to our consolidated results of operations. Level 3 instruments also include the fair value of contingent consideration related to completed acquisitions. The fair values are based on discounted cash flow analyses reflecting the likelihood of achieving specified performance measures or events and captures the contractual nature of the contingencies, commercial risk or time value of money. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2020 December 31, 2019 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 84 $ 84 Total assets $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 84 $ 84 Foreign exchange derivative assets Accrued expenses $ 0 $ 473 $ 0 $ 473 $ 0 $ 0 $ 0 $ 0 Contingent consideration - current Accrued expenses 0 0 14,757 14,757 0 0 17,116 17,116 Contingent consideration - long-term Other liabilities 0 0 2,415 2,415 0 0 2,415 2,415 1.25% Embedded cash conversion option Other liabilities 0 0 1 1 0 0 185 185 Total liabilities $ 0 $ 473 $ 17,173 $ 17,646 $ 0 $ 0 $ 19,716 $ 19,716 The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at March 31, 2020 are summarized as follows: (In thousands) Contingent Consideration 1.25% Notes Call Spread Overlay Balance at December 31, 2019 $ 19,531 $ (101 ) Additions 461 0 Payments/write-downs (2,820 ) 0 Fair value adjustments 0 100 Balance at March 31, 2020 $ 17,172 $ (1 ) The following table summarizes the quantitative information about our Level 3 fair value measurements at March 31, 2020: March 31, 2020 (In thousands, except the discount rate) Fair Value Valuation Technique Significant Unobservable Inputs Ranges of Inputs Weighted Average (1) Financial instruments: Contingent consideration $ 17,172 Discounted cash flow Discount rate 4% to 5% 4 % Revenue $0 to $62,500 $ 31,250 Registry members 0 to 1,551 776 Patient data volume 0 to 52,845 26,422 Projected year of payment 2020 to 2021 Total financial instruments $ 17,172 (1) The weighted average is calculated based upon the absolute fair value of the instruments. Long-term Investments The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at March 31, 2020 Cost March 31, 2020 December 31, 2019 Equity method investments (1) 5 $ 7,407 $ 11,531 $ 11,332 Cost less impairment 9 43,874 33,278 32,462 Total long-term equity investments 14 $ 51,281 $ 44,809 $ 43,794 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. As of March 31, 2020, it is not possible to estimate the fair value of our non-marketable cost and equity method investments, primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital and observable price changes in orderly transactions. Recovery of Long-term Investments During the three months ended March 31, 2019, we recovered $1.0 million from a third-party cost-method investment that we had previously impaired and is recognized in the Recovery of long-term investments. Long-term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility (as defined in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. The carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of March 31, 2020, since the effective interest rate on the 1.25% Notes approximates current market rates. Refer to Note 10, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	7. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three months ended March 31, 2020 and 2019 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three months ended March 31, 2020 and 2019. Three Months Ended March 31, (In thousands) 2020 2019 Cost of revenue: Software delivery, support and maintenance $ 575 $ 513 Client services 1,091 1,093 Total cost of revenue 1,666 1,606 Selling, general and administrative expenses 7,042 8,325 Research and development 2,395 2,877 Total stock-based compensation expense $ 11,103 $ 12,808 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three months ended March 31, 2020 and 2019. We granted stock-based awards as follows: Three Months Ended March 31, 2020 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 397 $ 8.19 Market-based restricted stock units with a service condition 595 $ 8.19 992 $ 8.19 During the three months ended March 31, 2020 and the year ended December 31, 2019, 0.9 million and 1.7 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the three months ended March 31, 2020 and 2019 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2020 and 2019 were 407 thousand and 508 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases On August 2, 2018, we announced that our Board of Directors approved a stock purchase program (the “2018 Program”) under which we may repurchase up to $250 million of our common stock through December 31, 2020. We repurchased 1.5 million of our common stock under the 2018 Program for a total of $9.7 million during the three months ended March 31, 2020. The approximate dollar value of shares that may yet be purchased under the 2018 Program is $92.1 million as of March 31, 2020. We repurchased 6.1 million shares of our common stock under the 2018 Program for a total of $64.9 million during the three months ended March 31, 2019. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	8. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2020 2019 Basic earnings (loss) per Common Share: Net loss $ (20,354 ) $ (7,977 ) Net loss attributable to non-controlling interests 0 424 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (20,354 ) $ (7,553 ) Weighted-average common shares outstanding 162,461 169,957 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.13 ) $ (0.04 ) Diluted earnings (loss) per Common Share: Net loss $ (20,354 ) $ (7,977 ) Net loss attributable to non-controlling interests 0 424 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (20,354 ) $ (7,553 ) Weighted-average common shares outstanding 162,461 169,957 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 Weighted-average common shares outstanding assuming dilution 162,461 169,957 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.13 ) $ (0.04 ) Due to the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three months ended March 31, 2020 and 2019, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for those periods, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2020 2019 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 48,032 26,738

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: March 31, 2020 December 31, 2019 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 546,047 $ (446,033 ) $ 100,014 $ 546,373 $ (437,640 ) $ 108,733 Customer contracts and relationships 701,322 (495,027 ) 206,295 702,034 (488,625 ) 213,409 Total $ 1,247,369 $ (941,060 ) $ 306,309 $ 1,248,407 $ (926,265 ) $ 322,142 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,361,115 1,362,017 Total $ 1,413,115 $ 1,414,017 Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2020 were as follows: (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Balance as of December 31, 2019 769,995 517,359 74,663 1,362,017 Foreign exchange translation (902 ) 0 0 (902 ) Balance as of March 31, 2020 $ 769,093 $ 517,359 $ 74,663 $ 1,361,115 There are $39.2

Debt

Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	10. Debt Debt outstanding, excluding lease obligations, consists of the following: March 31, 2020 December 31, 2019 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 177,942 $ 3,185 $ 174,757 $ 177,942 $ 4,697 $ 173,245 1.25% Cash Convertible Senior Notes 345,000 3,776 341,224 345,000 7,552 337,448 Senior Secured Credit Facility 540,000 4,796 535,204 410,000 5,224 404,776 Total debt $ 1,062,942 $ 11,757 $ 1,051,185 $ 932,942 $ 17,473 $ 915,469 Less: Debt payable within one year 371,519 768 370,751 364,653 188 364,465 Total long-term debt, less current maturities $ 691,423 $ 10,989 $ 680,434 $ 568,289 $ 17,285 $ 551,004 (1) Principal balance is $218,000 thousand; $177,942 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital Interest expense consists of the following: Three Months Ended March 31, (In thousands) 2020 2019 Interest expense $ 6,507 $ 6,229 Amortization of discounts and debt issuance costs 5,716 3,955 Total interest expense $ 12,223 $ 10,184 Interest expense related to 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes, included in the table above, consisted of the following: Three Months Ended March 31, (In thousands) 2020 2019 Coupon interest $ 1,555 $ 1,078 Amortization of discounts and debt issuance costs 5,288 3,577 Total interest expense related to the convertible notes $ 6,843 $ 4,655 Allscripts Senior Secured Credit Facility On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a $400 million senior secured term loan (the “Term Loan”) and a $900 million senior secured revolving facility (the “Revolving Facility”), each with a five-year As of March 31, 2020, $325.0 million under the Term Loan, $215.0 million under the Revolving Facility, and $1.0 million in letters of credit were outstanding under the Second Amended Credit Agreement. As of March 31, 2020, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 1.75%, which totaled 2.74%. We were in compliance with all covenants under the Second Amended Credit Agreement as of March 31, 2020. On August 7, 2019, we entered into a First Amendment to the Second Amended Credit Agreement in order to remain compliant with the covenants of our Second Amended Credit Agreement. The First Amendment provided the financial flexibility to settle the U.S. Department of Justice’s investigations as discussed in Note 14, “Contingencies” while maintaining our compliance with the covenants of our Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $0.8 million, of which a majority was capitalized. As of March 31, 2020, we had $684.0 million available, net of outstanding letters of credit, under our Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of our Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings or if we are unable to maintain compliance with applicable covenants. 0.875% Convertible Senior Notes The issuance in December 2019 of the combined $ 218.0 0.7 million in debt issuance costs, which were paid in January 2020. We have separately recorded liability and equity components of the 0.875% Convertible Senior Notes, including any discounts and issuance costs, by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes that do not include an embedded conversion option. The interest rate of 1.95 % was used to compute the initial fair value of the liability component, which totaled $ 177.9 time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million liability component was allocated to the equity component, which totaled $ 40.1 17.2 1.1 1.25% Cash Convertible Senior Notes As of March 31, 2020, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. The following table summarizes future debt payment obligations as of March 31, 2020: (In thousands) Total Remainder of 2020 2021 2022 2023 2024 Thereafter 0.875% Convertible Senior Notes (1) $ 218,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 218,000 1.25% Cash Convertible Senior Notes (2) 345,000 345,000 0 0 0 0 0 Term Loan 325,000 22,500 30,000 37,500 235,000 0 0 Revolving Facility (3) 215,000 0 0 0 215,000 0 0 Total debt $ 1,103,000 $ 367,500 $ 30,000 $ 37,500 $ 450,000 $ 0 $ 218,000 (1) Amount represents face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portion. (2) Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020. (3) Assumes no additional borrowings after March 31, 2020, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, “ Income Taxes” Three Months Ended March 31, (In thousands, except effective tax rate) 2020 2019 Loss from continuing operations before income taxes $ (20,701 ) $ (6,045 ) Income tax benefit (provision) $ 347 $ (1,932 ) Effective tax rate 1.7 % (32.0 %) Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate primarily due to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended March 31, 2020, compared with the prior year comparable period, differs primarily due to the fact that the permanent items, credits and the impact of foreign earnings had less impact on the pre-tax loss of $20.7 million in the three months ended March 31, 2020, compared to the impacts of these items on a pre-tax loss of $6.0 million for the three months ended March 31, 2019. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the three months ended March 31, 2020, we recorded valuation allowances of $1.6 million related to U.S. and foreign net operating loss carryforwards. Our unrecognized income tax benefits were $21.6 million and $20.6 million as of March 31, 2020 and December 31, 2019, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted considering changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	12. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2020 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 473 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 0 N/A 1.25% Embedded cash conversion option N/A Other liabilities 1 Total derivatives $ 0 $ 474 December 31, 2019 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 84 N/A 1.25% Embedded cash conversion option N/A Other liabilities 185 Total derivatives $ 84 $ 185 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of March 31, 2020, there were 9 forward contracts outstanding that were staggered to mature monthly starting in April 2020 December 2020 The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended March 31, 2020 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended March 31, 2020 Foreign exchange contracts $ (473 ) Cost of Revenue $ 0 Selling, general and administrative expenses 0 Research and development $ 0 Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended March 31, 2019 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended March 31, 2019 Foreign exchange contracts $ 151 Cost of Revenue $ 7 Selling, general and administrative expenses 5 Research and development $ 7 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2020 2019 1.25% Call Option $ (84 ) $ (6,074 ) 1.25% Embedded cash conversion option 184 6,449 Net income included in Other income, net $ 100 $ 375

Other Comprehensive Income

Other Comprehensive Income	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Other Comprehensive Income	13. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2019 (1) $ (4,392 ) $ 0 $ (4,392 ) Other comprehensive income (loss) before reclassifications (2,512 ) (351 ) (2,863 ) Net other comprehensive loss (2,512 ) (351 ) (2,863 ) Balance as of March 31, 2020 (2) $ (6,904 ) $ (351 ) $ (7,255 ) (1) (2) (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2018 (1) $ (5,584 ) $ 195 $ (5,389 ) Other comprehensive income (loss) before reclassifications 695 111 806 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (14 ) (14 ) Net other comprehensive income 695 97 792 Balance as of March 31, 2019 (2) $ (4,889 ) $ 292 $ (4,597 ) (1) (2) Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2020 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,512 ) $ 0 $ (2,512 ) $ 695 $ 0 $ 695 Foreign exchange contracts: Net (losses) gains arising during the period (473 ) 122 (351 ) 151 (40 ) 111 Net losses (gains) reclassified into income 0 0 0 (19 ) 5 (14 ) Net change in unrealized (losses) gains on foreign exchange contracts (473 ) 122 (351 ) 132 (35 ) 97 Net (loss) gain on cash flow hedges (473 ) 122 (351 ) 132 (35 ) 97 Other comprehensive (loss) income $ (2,985 ) $ 122 $ (2,863 ) $ 827 $ (35 ) $ 792

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Contingencies	14. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, except as set forth below with respected to the expected resolution of the Practice Fusion investigations, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these additional legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained for Horizon Clinicals in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. In August 2018, McKesson received an additional CID seeking similar information for Paragon. McKesson has agreed, with respect to the CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August 6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including the investigation by the U.S. Attorney’s Office for the District of Vermont, and we announced that on January 27, 2020, Practice Fusion entered into a deferred prosecution agreement and various civil settlement agreements, including with the Medicaid programs for each U.S. state, the District of Columbia and Puerto Rico (collectively, the “Settlement Agreements”) resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. The Settlement Agreements require Practice Fusion to, among other matters, pay a criminal fine of $25.3 million, a forfeiture payment of $959,700 and a civil settlement of $118.6 million, which includes $5.2 million designated for the state Medicaid program expenditures. The terms of Settlement Agreements resolved, among other things, allegations that Practice Fusion, long before its acquisition by Allscripts and concerning conduct about which Allscripts was unaware at the time of the acquisition, violated the AKS through the manner by which a sponsored Clinical Decision Support arrangement was sold to an opioid manufacturer and other AKS allegations made by the DOJ against Practice Fusion, as well as False Claims Act allegations pertaining to Meaningful Use payments the federal government made to users of Practice Fusion’s EHR system. In April 2020, Practice Fusion amended its civil settlement agreement with the DOJ by revising the timing of certain of the payments required to be made by Practice Fusion. Pursuant to the amendment, the Federal settlement amounts that were otherwise owed in the Company’s second and third fiscal quarters were reduced by half, and the balance of the Federal settlement amount owed by Practice Fusion will become due in January 2021.

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Business Segments	15. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. During the first quarter of 2020, we realigned our reporting structure to organize the Company around strategic business units to maximize delivery of client commitments, operational effectiveness and competitiveness. As a result, we have three operating segments, (i) Core Clinical and Financial Solutions, (ii) Data, Analytics and Care Coordination and (iii) EPSi TM TM Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. The “Unallocated Amounts” category also includes (i) corporate general and administrative expenses (including marketing expenses) and (ii) revenue and the associated cost from the resale of certain ancillary products, primarily hardware. We do not track our assets by segment. Three Months Ended March 31, (In thousands) 2020 2019 Revenue: Core Clinical and Financial Solutions $ 321,539 $ 341,896 Data, Analytics and Care Coordination 82,062 74,259 Unallocated Amounts 13,112 15,894 Total revenue $ 416,713 $ 432,049 Gross profit: Core Clinical and Financial Solutions $ 102,414 $ 119,337 Data, Analytics and Care Coordination 51,889 50,120 Unallocated Amounts 2,658 4,638 Total gross profit $ 156,961 $ 174,095 Income (loss) from operations: Core Clinical and Financial Solutions $ 27,534 $ 42,498 Data, Analytics and Care Coordination 19,361 17,696 Unallocated Amounts (56,095 ) (57,549 ) Total income (loss) from operations $ (9,200 ) $ 2,645

Supplemental Disclosures

Supplemental Disclosures	3 Months Ended
	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	16. Supplemental Disclosures Supplemental Consolidated Statements of Cash Flows Information The majority of the restricted cash balance as of March 31, 2020 and 2019 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016, to be used by Netsmart to facilitate the integration of Allscripts’ former Homecare TM March 31, (In thousands) 2020 2019 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 204,308 $ 137,167 Restricted cash 7,824 10,681 Total cash, cash equivalents and restricted cash $ 212,132 $ 147,848

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2020 and 2019 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates.
Change in Presentation	Change in Presentation During the first quarter of 2020, we changed our reportable segments from Provider, Veradigm and Unallocated to Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 15 “Business Segments” for further discussion on the impact of the change. Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported prior period financial results.
Recently Adopted Accounting Pronouncements	Significant Accounting Policies We adopted Accounting Standards Update No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” In March 2020, the FASB issued Accounting Standards Update No. 2020-04, “Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), which provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 will be effective for all entities as of March 12, 2020 through December 31, 2022. We adopted ASU 2020-04 on March 12, 2020 , and the adoption had no impact on our consolidated financial statements.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued Accounting Standards Update No. 2019-12, “ Income Taxes (Topic 740) We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2020
Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients	The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2020 Revenue related to deferred revenue balance at beginning of period $ 140,132 Revenue related to new performance obligations satisfied during the period 216,990 Revenue recognized under "right-to-invoice" expedient 58,059 Reimbursed travel expenses, shipping and other revenue 1,532 Total revenue $ 416,713 (In thousands) Three Months Ended March 31, 2019 Revenue related to deferred revenue balance at beginning of period $ 126,184 Revenue related to new performance obligations satisfied during the period 248,221 Revenue recognized under "right-to-invoice" expedient 55,923 Reimbursed travel expenses, shipping and other revenue 1,721 Total revenue $ 432,049
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Three Months Ended March 31, (In thousands) 2020 2019 Revenue: Recurring revenue $ 341,219 $ 348,636 Non-recurring revenue 75,494 83,413 Total revenue $ 416,713 $ 432,049
Summary of Changes in Estimate of Credit Losses for Contract Assets	Changes in the estimate of credit losses for contract assets are presented in the table below. (In thousands) Total Balance at January 1, 2020 $ 5,341 Current period provision 0 Balance at March 31, 2020 $ 5,341 Less: Contract assets, short-term 1,068 Total contract assets, long-term $ 4,273
Revenue by Segment [Member]
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	Three Months Ended March 31, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 176,800 $ 76,412 $ 10,400 $ 263,612 Client services 144,739 5,650 2,712 153,101 Total revenue $ 321,539 $ 82,062 $ 13,112 $ 416,713 Three Months Ended March 31, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 193,278 $ 69,357 $ 12,877 $ 275,512 Client services 148,618 4,902 3,017 156,537 Total revenue $ 341,896 $ 74,259 $ 15,894 $ 432,049

Accounts Receivables (Tables)

Accounts Receivables (Tables)	3 Months Ended
	Mar. 31, 2020
Trade Accounts Receivable [Member]
Accounts Notes And Loans Receivable [Line Items]
Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable	Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below. (In thousands) Total Balance at January 1, 2020 $ 36,490 Current period provision 994 Write-offs (1,892 ) Recoveries 30 Balance at March 31, 2020 $ 35,622

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Lessee Disclosure [Abstract]
Summary of Operating Costs Associated with Leased Assets	Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating lease cost (1) $ 6,922 $ 6,717 Less: Sublease income (603 ) (802 ) Total operating lease costs $ 6,319 $ 5,915 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of operations.
Supplemental Information for Operating Leases	Supplemental information for operating leases is as follows: (In thousands) Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating cash flows from operating leases $ 7,421 $ 7,287 Right-of-use assets obtained in exchange for operating lease obligations $ 19,913 $ 124,811
Summary of Balance Sheet Location and Balances for Operating Leases	The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) March 31, 2020 December 31, 2019 Right-of-use assets - operating leases $ 110,469 $ 98,020 Current operating lease liabilities $ 21,910 $ 23,137 Long-term operating lease liabilities $ 108,068 $ 95,162 Weighted average remaining lease term (in years) 6 6 Weighted average discount rate 3.6 % 4.4 %
Summary of Future Maturities of Lease and Non-Lease Components	The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of March 31, 2020. March 31, 2020 (In thousands) Operating Leases Remainder of 2020 $ 20,097 2021 25,996 2022 24,355 2023 22,177 2024 16,633 Thereafter 35,831 Total lease liabilities 145,089 Less: Amount representing interest (15,111 ) Less: Short-term lease liabilities (21,910 ) Total long-term lease liabilities $ 108,068

Fair Value Measurements and L_2

Fair Value Measurements and Long-term Investments (Tables)	3 Months Ended
	Mar. 31, 2020
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2020 December 31, 2019 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 84 $ 84 Total assets $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 84 $ 84 Foreign exchange derivative assets Accrued expenses $ 0 $ 473 $ 0 $ 473 $ 0 $ 0 $ 0 $ 0 Contingent consideration - current Accrued expenses 0 0 14,757 14,757 0 0 17,116 17,116 Contingent consideration - long-term Other liabilities 0 0 2,415 2,415 0 0 2,415 2,415 1.25% Embedded cash conversion option Other liabilities 0 0 1 1 0 0 185 185 Total liabilities $ 0 $ 473 $ 17,173 $ 17,646 $ 0 $ 0 $ 19,716 $ 19,716
Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at March 31, 2020 are summarized as follows: (In thousands) Contingent Consideration 1.25% Notes Call Spread Overlay Balance at December 31, 2019 $ 19,531 $ (101 ) Additions 461 0 Payments/write-downs (2,820 ) 0 Fair value adjustments 0 100 Balance at March 31, 2020 $ 17,172 $ (1 )
Summary of Quantitative Information About Fair Value Measurements	The following table summarizes the quantitative information about our Level 3 fair value measurements at March 31, 2020: March 31, 2020 (In thousands, except the discount rate) Fair Value Valuation Technique Significant Unobservable Inputs Ranges of Inputs Weighted Average (1) Financial instruments: Contingent consideration $ 17,172 Discounted cash flow Discount rate 4% to 5% 4 % Revenue $0 to $62,500 $ 31,250 Registry members 0 to 1,551 776 Patient data volume 0 to 52,845 26,422 Projected year of payment 2020 to 2021 Total financial instruments $ 17,172 (1) The weighted average is calculated based upon the absolute fair value of the instruments.
Long-Term Equity and Cost Method Investments [Member]
Summary of Long-term Equity Investments Included in Other Assets	The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at March 31, 2020 Cost March 31, 2020 December 31, 2019 Equity method investments (1) 5 $ 7,407 $ 11,531 $ 11,332 Cost less impairment 9 43,874 33,278 32,462 Total long-term equity investments 14 $ 51,281 $ 44,809 $ 43,794 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Share-Based Compensation Expense	Three Months Ended March 31, (In thousands) 2020 2019 Cost of revenue: Software delivery, support and maintenance $ 575 $ 513 Client services 1,091 1,093 Total cost of revenue 1,666 1,606 Selling, general and administrative expenses 7,042 8,325 Research and development 2,395 2,877 Total stock-based compensation expense $ 11,103 $ 12,808
Share-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended March 31, 2020 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 397 $ 8.19 Market-based restricted stock units with a service condition 595 $ 8.19 992 $ 8.19

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2020 2019 Basic earnings (loss) per Common Share: Net loss $ (20,354 ) $ (7,977 ) Net loss attributable to non-controlling interests 0 424 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (20,354 ) $ (7,553 ) Weighted-average common shares outstanding 162,461 169,957 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.13 ) $ (0.04 ) Diluted earnings (loss) per Common Share: Net loss $ (20,354 ) $ (7,977 ) Net loss attributable to non-controlling interests 0 424 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (20,354 ) $ (7,553 ) Weighted-average common shares outstanding 162,461 169,957 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 Weighted-average common shares outstanding assuming dilution 162,461 169,957 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.13 ) $ (0.04 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2020 2019 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 48,032 26,738

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: March 31, 2020 December 31, 2019 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 546,047 $ (446,033 ) $ 100,014 $ 546,373 $ (437,640 ) $ 108,733 Customer contracts and relationships 701,322 (495,027 ) 206,295 702,034 (488,625 ) 213,409 Total $ 1,247,369 $ (941,060 ) $ 306,309 $ 1,248,407 $ (926,265 ) $ 322,142 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,361,115 1,362,017 Total $ 1,413,115 $ 1,414,017
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2020 were as follows: (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Balance as of December 31, 2019 769,995 517,359 74,663 1,362,017 Foreign exchange translation (902 ) 0 0 (902 ) Balance as of March 31, 2020 $ 769,093 $ 517,359 $ 74,663 $ 1,361,115

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Instrument [Line Items]
Debt Outstanding Excluding Lease Obligations	Debt outstanding, excluding lease obligations, consists of the following: March 31, 2020 December 31, 2019 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 177,942 $ 3,185 $ 174,757 $ 177,942 $ 4,697 $ 173,245 1.25% Cash Convertible Senior Notes 345,000 3,776 341,224 345,000 7,552 337,448 Senior Secured Credit Facility 540,000 4,796 535,204 410,000 5,224 404,776 Total debt $ 1,062,942 $ 11,757 $ 1,051,185 $ 932,942 $ 17,473 $ 915,469 Less: Debt payable within one year 371,519 768 370,751 364,653 188 364,465 Total long-term debt, less current maturities $ 691,423 $ 10,989 $ 680,434 $ 568,289 $ 17,285 $ 551,004 (1) Principal balance is $218,000 thousand; $177,942 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital
Interest Expense	Interest expense consists of the following: Three Months Ended March 31, (In thousands) 2020 2019 Interest expense $ 6,507 $ 6,229 Amortization of discounts and debt issuance costs 5,716 3,955 Total interest expense $ 12,223 $ 10,184
Summary of Future Debt Payment Obligations	The following table summarizes future debt payment obligations as of March 31, 2020: (In thousands) Total Remainder of 2020 2021 2022 2023 2024 Thereafter 0.875% Convertible Senior Notes (1) $ 218,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 218,000 1.25% Cash Convertible Senior Notes (2) 345,000 345,000 0 0 0 0 0 Term Loan 325,000 22,500 30,000 37,500 235,000 0 0 Revolving Facility (3) 215,000 0 0 0 215,000 0 0 Total debt $ 1,103,000 $ 367,500 $ 30,000 $ 37,500 $ 450,000 $ 0 $ 218,000 (1) Amount represents face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portion. (2) Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020. (3) Assumes no additional borrowings after March 31, 2020, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.
0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes	Interest expense related to 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes, included in the table above, consisted of the following: Three Months Ended March 31, (In thousands) 2020 2019 Coupon interest $ 1,555 $ 1,078 Amortization of discounts and debt issuance costs 5,288 3,577 Total interest expense related to the convertible notes $ 6,843 $ 4,655

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Effective Tax Rates	The effective tax rates were as follows: Three Months Ended March 31, (In thousands, except effective tax rate) 2020 2019 Loss from continuing operations before income taxes $ (20,701 ) $ (6,045 ) Income tax benefit (provision) $ 347 $ (1,932 ) Effective tax rate 1.7 % (32.0 %)

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2020 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 473 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 0 N/A 1.25% Embedded cash conversion option N/A Other liabilities 1 Total derivatives $ 0 $ 474 December 31, 2019 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 84 N/A 1.25% Embedded cash conversion option N/A Other liabilities 185 Total derivatives $ 84 $ 185 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended March 31, 2020 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended March 31, 2020 Foreign exchange contracts $ (473 ) Cost of Revenue $ 0 Selling, general and administrative expenses 0 Research and development $ 0 Amount of Gain (Loss) Recognized in OCI Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Ended March 31, 2019 Location of Gain (Loss) Reclassified from AOCI into Income Three Months Ended March 31, 2019 Foreign exchange contracts $ 151 Cost of Revenue $ 7 Selling, general and administrative expenses 5 Research and development $ 7
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2020 2019 1.25% Call Option $ (84 ) $ (6,074 ) 1.25% Embedded cash conversion option 184 6,449 Net income included in Other income, net $ 100 $ 375

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2019 (1) $ (4,392 ) $ 0 $ (4,392 ) Other comprehensive income (loss) before reclassifications (2,512 ) (351 ) (2,863 ) Net other comprehensive loss (2,512 ) (351 ) (2,863 ) Balance as of March 31, 2020 (2) $ (6,904 ) $ (351 ) $ (7,255 ) (1) (2) (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2018 (1) $ (5,584 ) $ 195 $ (5,389 ) Other comprehensive income (loss) before reclassifications 695 111 806 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (14 ) (14 ) Net other comprehensive income 695 97 792 Balance as of March 31, 2019 (2) $ (4,889 ) $ 292 $ (4,597 ) (1) (2)
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2020 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,512 ) $ 0 $ (2,512 ) $ 695 $ 0 $ 695 Foreign exchange contracts: Net (losses) gains arising during the period (473 ) 122 (351 ) 151 (40 ) 111 Net losses (gains) reclassified into income 0 0 0 (19 ) 5 (14 ) Net change in unrealized (losses) gains on foreign exchange contracts (473 ) 122 (351 ) 132 (35 ) 97 Net (loss) gain on cash flow hedges (473 ) 122 (351 ) 132 (35 ) 97 Other comprehensive (loss) income $ (2,985 ) $ 122 $ (2,863 ) $ 827 $ (35 ) $ 792

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended March 31, (In thousands) 2020 2019 Revenue: Core Clinical and Financial Solutions $ 321,539 $ 341,896 Data, Analytics and Care Coordination 82,062 74,259 Unallocated Amounts 13,112 15,894 Total revenue $ 416,713 $ 432,049 Gross profit: Core Clinical and Financial Solutions $ 102,414 $ 119,337 Data, Analytics and Care Coordination 51,889 50,120 Unallocated Amounts 2,658 4,638 Total gross profit $ 156,961 $ 174,095 Income (loss) from operations: Core Clinical and Financial Solutions $ 27,534 $ 42,498 Data, Analytics and Care Coordination 19,361 17,696 Unallocated Amounts (56,095 ) (57,549 ) Total income (loss) from operations $ (9,200 ) $ 2,645

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	3 Months Ended
	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	The majority of the restricted cash balance as of March 31, 2020 and 2019 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016, to be used by Netsmart to facilitate the integration of Allscripts’ former Homecare TM March 31, (In thousands) 2020 2019 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 204,308 $ 137,167 Restricted cash 7,824 10,681 Total cash, cash equivalents and restricted cash $ 212,132 $ 147,848

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)Revenue_Stream	Mar. 31, 2019USD ($)	Jan. 01, 2020USD ($)	Dec. 31, 2019USD ($)
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams | Revenue_Stream	2
Total backlog	$ 4,500
Total backlog, percentage, year one	32.00%
Total backlog, percentage after year one	68.00%
ASU 2016-13
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Effect of ASU on retained earnings			$ (5.3)
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	$ 7.5	$ 7.6
Prepaid Expenses and Other Current Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	19.6			$ 20.8
Other Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	$ 34.4			$ 32.9

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 140,132	$ 126,184
Revenue related to new performance obligations satisfied during the period	216,990	248,221
Revenue recognized under "right-to-invoice" expedient	58,059	55,923
Reimbursed travel expenses, shipping and other revenue	1,532	1,721
Total revenue	$ 416,713	$ 432,049

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation Of Revenue [Line Items]
Recurring revenue	$ 341,219	$ 348,636
Non-recurring revenue	75,494	83,413
Total revenue	416,713	432,049
Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	13,112	15,894
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	321,539	341,896
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	82,062	74,259
Software delivery, Support and Maintenance [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	263,612	275,512
Software delivery, Support and Maintenance [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	10,400	12,877
Software delivery, Support and Maintenance [Member] | Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	176,800	193,278
Software delivery, Support and Maintenance [Member] | Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	76,412	69,357
Client services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	153,101	156,537
Client services [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,712	3,017
Client services [Member] | Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	144,739	148,618
Client services [Member] | Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 5,650	$ 4,902

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Summary of Changes in Estimate of Credit Losses for Contract Assets (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Balance at January 1, 2020	$ 5,341
Current period provision	0
Balance at March 31, 2020	5,341
Contract assets, allowance	1,068	$ 0
Total contract assets, long-term	$ 4,273	$ 0

Accounts Receivables - Addition

Accounts Receivables - Additional Information (Details) - Trade Accounts Receivable [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Jan. 01, 2020	Dec. 31, 2019
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss	$ 35,622		$ 36,490
ASU 2016-13
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss		$ 12,600

Accounts Receivables - Schedule

Accounts Receivables - Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable (Details) - Trade Accounts Receivable [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Accounts Notes And Loans Receivable [Line Items]
Balance at January 1, 2020	$ 36,490
Current period provision	994
Write-offs	(1,892)
Recoveries	30
Balance at March 31, 2020	$ 35,622

Leases - Additional Information

Leases - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020
Minimum [Member]
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	9 years
Operating leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year

Leases - Summary of Operating C

Leases - Summary of Operating Costs Associated with Leased Assets (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	[1]	$ 6,922	$ 6,717
Less: Sublease income		(603)	(802)
Total operating lease costs		$ 6,319	$ 5,915
[1]	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of operations.

Leases - Supplemental Informati

Leases - Supplemental Information for Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating cash flows from operating leases	$ 7,421	$ 7,287
Right-of-use assets obtained in exchange for operating lease obligations	$ 19,913	$ 124,811

Leases - Summary of Balance She

Leases - Summary of Balance Sheet Location and Balances for Operating Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Right-of-use assets - operating leases	$ 110,469	$ 98,020
Current operating lease liabilities	21,910	23,137
Long-term operating lease liabilities	$ 108,068	$ 95,162
Weighted average remaining lease term (in years)	6 years	6 years
Weighted average discount rate	3.60%	4.40%

Leases - Summary of Future Matu

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating Leases [Abstract]
Operating Leases, Remainder of 2020	$ 20,097
Operating Leases, 2021	25,996
Operating Leases, 2022	24,355
Operating Leases, 2023	22,177
Operating Leases, 2024	16,633
Operating Leases, Thereafter	35,831
Operating Leases, Total lease liabilities	145,089
Operating Leases, Less: Amount representing interest	(15,111)
Operating Leases, Less: Short-term lease liabilities	(21,910)	$ (23,137)
Operating Leases, Total long-term lease liabilities	$ 108,068	$ 95,162

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($)	Jul. 02, 2019	Mar. 01, 2019
ACC Pinnacle and Diabetes Collaborative Registries [Member]
Business Acquisition [Line Items]
Total purchase price	$ 19,700,000
Purchase price initial payment	11,700,000
Potential milestone/earnout payments	5,000,000
ACC Pinnacle and Diabetes Collaborative Registries [Member] | Maximum [Member]
Business Acquisition [Line Items]
Potential milestone/earnout payments	$ 8,000,000
Pulse8, Inc. [Member]
Business Acquisition [Line Items]
Acquisition of outstanding minority interest		$ 53,800,000

Fair Value Measurements and L_3

Fair Value Measurements and Long-term Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Recovery of long-term investments	$ 0	$ 1,045
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%
1.25% Call Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%

Fair Value Measurements and L_4

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	$ 0	$ 84
Total liabilities	17,646	19,716
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	473	0
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	14,757	17,116
Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	2,415	2,415
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	1	185
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 1 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 1 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	473	0
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	473	0
Level 2 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 2 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	84
Total liabilities	17,173	19,716
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 3 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	14,757	17,116
Level 3 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	2,415	2,415
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	1	185
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	84
1.25% Call Option [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 0	$ 84

Fair Value Measurements and L_5

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)	Mar. 31, 2020
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%

Fair Value Measurements and L_6

Fair Value Measurements and Long-term Investments - Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2019	$ 19,531
Additions	461
Payments/write-downs	(2,820)
Fair value adjustments	0
Balance at March 31, 2020	17,172
1.25% Notes Call Spread Overlay [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at December 31, 2019	(101)
Additions	0
Payments/write-downs	0
Fair value adjustments	100
Balance at March 31, 2020	$ (1)

Fair Value Measurements and L_7

Fair Value Measurements and Long-term Investments - Summary of Quantitative Information About Fair Value Measurements (Detail) - Level 3 [Member]	3 Months Ended
	Mar. 31, 2020USD ($)RegistryMemberPatientDataVolume
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial instruments	$ 17,172,000
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Projected year of payment	2020
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Projected year of payment	2021
Revenue [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	0
Revenue [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	62,500,000
Revenue [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	31,250,000	[1]
Registry Members [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	0
Registry Members [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	1,551
Registry Members [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	776	[1]
Patient Data Volume [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	0
Patient Data Volume [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	52,845
Patient Data Volume [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	26,422	[1]
Contingent Consideration [Member] | Discounted Cash Flow [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial instruments	$ 17,172,000
Contingent Consideration [Member] | Discounted Cash Flow [Member] | Discount Rate [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	4
Contingent Consideration [Member] | Discounted Cash Flow [Member] | Discount Rate [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	5
Contingent Consideration [Member] | Discounted Cash Flow [Member] | Discount Rate [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	4	[1]
[1]	The weighted average is calculated based upon the absolute fair value of the instruments.

Fair Value Measurements and L_8

Fair Value Measurements and Long-term Investments - Summary of Long-term Equity Investments Included in Other Assets (Detail) $ in Thousands		3 Months Ended
		Mar. 31, 2020USD ($)Investment	Dec. 31, 2019USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	5
Cost less impairments, Number of investees | Investment		9
Total long-term equity investments, Number of Investees | Investment		14
Equity method investments, Original Cost	[1]	$ 7,407
Cost less impairment, Original Cost		43,874
Total long-term equity investments, Original Cost		51,281
Equity method investments, Carrying Value	[1]	11,531	$ 11,332
Cost less impairment, Carrying Value		33,278	32,462
Total long-term equity investments, Carrying Value		$ 44,809	$ 43,794
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Aug. 02, 2018
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0	$ 0
Stock options granted	0	0
Share issued, exercise of options and release of stock awards	900,000		1,700,000
Shares settled for tax withholding	407,000	508,000
Common stock repurchased, amount	$ 9,714,000	$ 65,070,000
August 2018 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount				$ 250,000,000
Stock repurchase program, Value of shares yet to be purchased	$ 92,100,000
Common stock repurchased, shares	1,500,000	6,100,000
Common stock repurchased, amount	$ 9,700,000	$ 64,900,000

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 11,103	$ 12,808
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,666	1,606
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	575	513
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,091	1,093
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	7,042	8,325
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,395	$ 2,877

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	992
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 8.19
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	397
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 8.19
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	595
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 8.19

Earnings (Loss) Per Share - Cal

Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic earnings (loss) per Common Share:
Net loss	$ (20,354)	$ (7,977)
Net loss attributable to non-controlling interests	0	424
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (20,354)	$ (7,553)
Weighted-average common shares outstanding	162,461	169,957
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$ (0.13)	$ (0.04)
Diluted earnings (loss) per Common Share:
Net loss	$ (20,354)	$ (7,977)
Net loss attributable to non-controlling interests	0	424
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (20,354)	$ (7,553)
Weighted-average common shares outstanding	162,461	169,957
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants	0	0
Weighted-average common shares outstanding assuming dilution	162,461	169,957
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$ (0.13)	$ (0.04)

Earnings (Loss) Per Share - Ant

Earnings (Loss) Per Share - Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	48,032	26,738

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,247,369	$ 1,248,407
Accumulated Amortization	(941,060)	(926,265)
Intangible Assets, Net	306,309	322,142
Registered trademarks	52,000	52,000
Goodwill	1,361,115	1,362,017
Total	1,413,115	1,414,017
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	546,047	546,373
Accumulated Amortization	(446,033)	(437,640)
Intangible Assets, Net	100,014	108,733
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	701,322	702,034
Accumulated Amortization	(495,027)	(488,625)
Intangible Assets, Net	$ 206,295	$ 213,409

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Goodwill [Line Items]
Goodwill	$ 1,362,017
Foreign exchange translation	(902)
Goodwill, net	1,361,115
Unallocated Amounts [Member]
Goodwill [Line Items]
Goodwill	74,663
Foreign exchange translation	0
Goodwill, net	74,663
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill	769,995
Foreign exchange translation	(902)
Goodwill, net	769,093
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill	517,359
Foreign exchange translation	0
Goodwill, net	$ 517,359

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 39.2	$ 39.2

Debt - Debt Outstanding Excludi

Debt - Debt Outstanding Excluding Lease Obligations (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Principal Balance	$ 1,062,942	$ 932,942
Unamortized Discount and Debt Issuance Costs	11,757	17,473
Net Carrying Amount	1,051,185	915,469
Principal Balance, Current	371,519	364,653
Unamortized Discount and Debt Issuance Costs, Current	768	188
Net Carrying Amount, Current	370,751	364,465
Principal Balance, Noncurrent	691,423	568,289
Unamortized Discount and Debt Issuance Costs, Noncurrent	10,989	17,285
Net Carrying Amount, Noncurrent	680,434	551,004
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	177,942	177,942
Unamortized Discount and Debt Issuance Costs	3,185	4,697
Net Carrying Amount	174,757	173,245
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	345,000
Unamortized Discount and Debt Issuance Costs	3,776	7,552
Net Carrying Amount	341,224	337,448
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	540,000	410,000
Unamortized Discount and Debt Issuance Costs	4,796	5,224
Net Carrying Amount	$ 535,204	$ 404,776

Debt - Debt Outstanding Exclu_2

Debt - Debt Outstanding Excluding Lease Obligations (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt recognized	$ 1,062,942	$ 932,942
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	218,000	218,000
Debt recognized	177,942	177,942
Additional Paid-In Capital [Member] | 0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Additional paid-in capital recognized	$ 40,058	$ 40,058

Debt - Interest Expense (Detail

Debt - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Total interest expense	$ 12,223	$ 10,184
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	6,507	6,229
Amortization of discounts and debt issuance costs	5,716	3,955
Total interest expense	$ 12,223	$ 10,184

Debt - Interest Expense Related

Debt - Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes (Detail) - 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Coupon interest	$ 1,555	$ 1,078
Amortization of discounts and debt issuance costs	5,288	3,577
Total interest expense related to the convertible notes	$ 6,843	$ 4,655

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Aug. 07, 2019	Feb. 15, 2018	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Debt instrument principal amount			$ 932,942,000	$ 1,062,942,000
Debt issuance costs				758,000	$ 0
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, amount available				684,000,000
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			410,000,000	540,000,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			177,942,000	177,942,000
Debt instrument principal amount			$ 218,000,000	218,000,000
Interest rate			0.875%
Debt issuance costs			$ 700,000
Percentage of interest rate used to to compute the initial fair value of the liability component			1.95%
Debt instrument, initial fair value of liability component			$ 177,900,000
Debt instrument, net carrying value of equity component				20,000,000
0.875% Convertible Senior Notes [Member] | Additional Paid-In Capital [Member]
Debt Instrument [Line Items]
Debt instrument, equity component amount			40,058,000	40,058,000
Payments of capped call fees			17,200,000
Debt discounts and issuance costs			1,100,000
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 345,000,000	$ 345,000,000
Interest rate				1.25%
Letter of Credit [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance		$ 50,000,000
Swing Loans [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance		10,000,000
Foreign Currencies [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance		100,000,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity		$ 400,000,000
Senior secured credit facilities term, years		5 years
Line of credit facility, frequency of payments				The Term Loan is repayable in quarterly installments, which began on June 30, 2018.
Second Amended Credit Agreement [Member] | Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				$ 325,000,000
Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				$ 215,000,000
Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage				2.74%
Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument, variable interest rate				1.75%
Second Amended Credit Agreement [Member] | Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Letters of credit outstanding				$ 1,000,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity		$ 900,000,000
Senior secured credit facilities term, years		5 years
Fees and other costs, incurred	$ 800,000

Debt - Summary of Future Debt P

Debt - Summary of Future Debt Payment Obligations (Detail) $ in Thousands	Mar. 31, 2020USD ($)
Debt Instrument [Line Items]
Total	$ 1,103,000
Remainder of 2020	367,500
2021	30,000
2022	37,500
2023	450,000
2024	0
Thereafter	218,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	218,000
Remainder of 2020	0
2021	0
2022	0
2023	0
2024	0
Thereafter	218,000
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	345,000
Remainder of 2020	345,000
2021	0
2022	0
2023	0
2024	0
Thereafter	0
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Total	325,000
Remainder of 2020	22,500
2021	30,000
2022	37,500
2023	235,000
2024	0
Thereafter	0
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total	215,000
Remainder of 2020	0
2021	0
2022	0
2023	215,000
2024	0
Thereafter	$ 0

Debt - Summary of Future Debt_2

Debt - Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	Jun. 18, 2013
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Maturity date	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Loss from continuing operations before income taxes	$ (20,701)	$ (6,045)
Income tax benefit (provision)	$ 347	$ (1,932)
Effective tax rate	1.70%	(32.00%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Pre-tax loss	$ 20,701	$ 6,045
Cumulative operating income loss period considered	3 years
Unrecognized income tax benefits	$ 21,600		$ 20,600
U.S. and Foreign Net Operating Loss Carryforwards [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance	$ 1,600

Derivative Financial Instrume_3

Derivative Financial Instruments - Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 0	$ 84
Derivative liability, fair value	474	185
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	0	0
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	473	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	0	84
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 1	$ 185

Derivative Financial Instrume_4

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020USD ($)Derivative	Mar. 31, 2020INR (₨)Derivative	Jun. 18, 2013USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	9	9
Derivative notional amount outstanding	$ 3,700,000	₨ 280,000,000
Unrealized derivatives gains included in accumulated other comprehensive (loss) income reclassified into income	$ 500,000
Estimated period of unrealized losses included in AOCI reclassified into income	9 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Apr. 30, 2020
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Dec. 31, 2020
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option			$ 82,800,000

Derivative Financial Instrume_5

Derivative Financial Instruments - Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI	$ (473)	$ 151
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	0	7
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	0	5
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	$ 0	$ 7

Derivative Financial Instrume_6

Derivative Financial Instruments - Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative Instruments Gain Loss [Line Items]
Net (loss) income included in Other income, net	$ 100	$ 375
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) income included in Other income, net	(84)	(6,074)
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) income included in Other income, net	$ 184	$ 6,449

Other Comprehensive Income - Co

Other Comprehensive Income - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	$ 1,285,188
Other comprehensive income (loss) before reclassifications	(2,863)	$ 806
Net (gains) losses reclassified from accumulated other comprehensive loss		(14)
Total other comprehensive (loss) income	(2,863)	792
Balance at the end of the period	1,241,780
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(4,392)	(5,584)
Other comprehensive income (loss) before reclassifications	(2,512)	695
Net (gains) losses reclassified from accumulated other comprehensive loss		0
Total other comprehensive (loss) income	(2,512)	695
Balance at the end of the period	(6,904)	(4,889)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	0	195
Other comprehensive income (loss) before reclassifications	(351)	111
Net (gains) losses reclassified from accumulated other comprehensive loss		(14)
Total other comprehensive (loss) income	(351)	97
Balance at the end of the period	(351)	292
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(4,392)	(5,389)
Balance at the end of the period	$ (7,255)	$ (4,597)

Other Comprehensive Income - _2

Other Comprehensive Income - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)		$ 68	$ (122)	$ (102)
Revaluation of tax effects	$ 149	$ 149

Other Comprehensive Income - In

Other Comprehensive Income - Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ (2,512)	$ 695
Other comprehensive (loss) income, Before-Tax Amount	(2,985)	827
Foreign currency translation adjustments, Tax Effect	0	0
Other comprehensive (loss) income, Tax Effect	122	(35)
Foreign currency translation adjustments, Net	(2,512)	695
Other comprehensive (loss) income, Net	(2,863)	792
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net (loss) gain, Before-Tax Amount	(473)	132
Derivatives qualifying as cash flow hedges, net losses (gains), Tax Effect	122	(35)
Derivatives qualifying as cash flow hedges, net (loss) gain, Net	(351)	97
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Before-Tax Amount	(473)	151
Derivatives qualifying as cash flow hedges, net losses (gains) rereclassified into income, Before-Tax Amountreclassified into income, Before-Tax Amount	0	(19)
Derivatives qualifying as cash flow hedges, net (loss) gain, Before-Tax Amount	(473)	132
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Tax Effect	122	(40)
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Tax Effect	0	5
Derivatives qualifying as cash flow hedges, net losses (gains), Tax Effect	122	(35)
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Net	(351)	111
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Net	0	(14)
Derivatives qualifying as cash flow hedges, net (loss) gain, Net	(351)	97
Other comprehensive (loss) income, Net	$ (351)	$ 97

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Practice Fusion, Inc. [Member] - US Department of Justice and US Attorney [Member]	3 Months Ended
	Mar. 31, 2020USD ($)
Criminal Fine [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 25,300,000
Forfeiture Payment [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	959,700
Civil Settlements [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	118,600,000
State Medicaid Program Expenditures [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 5,200,000

Business Segments - Additional

Business Segments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020Segment
Segment Reporting [Abstract]
Number of operating segments	3
Number of reportable segments	2

Business Segments - Revenues an

Business Segments - Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 416,713	$ 432,049
Gross profit	156,961	174,095
Income (loss) from operations	(9,200)	2,645
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	13,112	15,894
Gross profit	2,658	4,638
Income (loss) from operations	(56,095)	(57,549)
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	321,539	341,896
Gross profit	102,414	119,337
Income (loss) from operations	27,534	42,498
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	82,062	74,259
Gross profit	51,889	50,120
Income (loss) from operations	$ 19,361	$ 17,696

Supplemental Disclosures - Supp

Supplemental Disclosures - Supplemental Disclosures (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 204,308	$ 129,668	$ 137,167
Restricted cash	7,824	$ 7,871	10,681
Total cash, cash equivalents and restricted cash	$ 212,132		$ 147,848